CA3073669A1 - Compositions and methods for treating cancer - Google Patents

Compositions and methods for treating cancer Download PDF

Info

Publication number
CA3073669A1
CA3073669A1 CA3073669A CA3073669A CA3073669A1 CA 3073669 A1 CA3073669 A1 CA 3073669A1 CA 3073669 A CA3073669 A CA 3073669A CA 3073669 A CA3073669 A CA 3073669A CA 3073669 A1 CA3073669 A1 CA 3073669A1
Authority
CA
Canada
Prior art keywords
subject
onecut2
agent
day
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073669A
Other languages
English (en)
French (fr)
Inventor
Michael Freeman
Mirja ROTINEN
Ramachandran Murali
Sungyong YOU
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CA3073669A1 publication Critical patent/CA3073669A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
CA3073669A 2017-08-22 2018-08-22 Compositions and methods for treating cancer Pending CA3073669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548879P 2017-08-22 2017-08-22
US62/548,879 2017-08-22
PCT/US2018/047569 WO2019040647A1 (en) 2017-08-22 2018-08-22 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
CA3073669A1 true CA3073669A1 (en) 2019-02-28

Family

ID=65440144

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073669A Pending CA3073669A1 (en) 2017-08-22 2018-08-22 Compositions and methods for treating cancer

Country Status (8)

Country Link
US (1) US11529338B2 (https=)
EP (1) EP3672582B1 (https=)
JP (1) JP7293194B2 (https=)
CN (1) CN111182894A (https=)
AU (1) AU2018321950A1 (https=)
CA (1) CA3073669A1 (https=)
IL (1) IL272782A (https=)
WO (1) WO2019040647A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer
JP7822940B2 (ja) * 2019-10-07 2026-03-03 ディー．イー．ショウ リサーチ，エルエルシー Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン複素環式化合物
PL447378A1 (pl) * 2023-12-29 2025-06-30 Uniwersytet Medyczny W Lublinie Zastosowanie lepidylin w leczeniu nowotworu układu nerwowego.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6048877A (en) * 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents
US6218367B1 (en) 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US7892740B2 (en) 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
EP2245199B1 (en) 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US20140056807A1 (en) 2012-08-23 2014-02-27 Cedars-Sinai Medical Center Large oncosomes in human tumors and in circulation in patients with cancer
EP2968371A4 (en) * 2013-03-12 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
EP2986326B1 (en) 2013-04-15 2018-09-05 Cedars-Sinai Medical Center Methods for detecting cancer metastasis
US20170051149A1 (en) * 2014-04-29 2017-02-23 Ecole Normale Superieure De Lyon Azoaryls as reversibly modulatable tubulin inhibitors
JP2017518312A (ja) * 2014-06-05 2017-07-06 ユニバーシティ・オブ・カンザス マルメリン類似体および癌治療における使用方法
WO2015197909A1 (en) * 2014-06-27 2015-12-30 Fermion Oy Process for the preparation of a crystalline polymorph of 2-amino-3-hydroxy-n'-(2,3,4-trihydroxybenzyl)propanehydrazide (benserazide) hydrochloride
US11174518B2 (en) 2015-10-05 2021-11-16 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
US10927070B2 (en) 2016-06-09 2021-02-23 Cedars-Sinai Medical Center Compositions and methods for treating cancer

Also Published As

Publication number Publication date
AU2018321950A1 (en) 2020-03-19
JP2020531495A (ja) 2020-11-05
US11529338B2 (en) 2022-12-20
EP3672582A4 (en) 2021-05-05
IL272782A (en) 2020-04-30
EP3672582A1 (en) 2020-07-01
WO2019040647A1 (en) 2019-02-28
CN111182894A (zh) 2020-05-19
US20200188373A1 (en) 2020-06-18
EP3672582B1 (en) 2026-04-15
JP7293194B2 (ja) 2023-06-19

Similar Documents

Publication Publication Date Title
US12421185B2 (en) Compositions and methods for treating cancer
JP7582694B2 (ja) Ｍｅｋ阻害剤及びその治療的使用
CN112225724B (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
ES2981114T3 (es) 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios
US20200325115A1 (en) Heterocyclic compounds as immunomodulators
BR112020004559A2 (pt) inibidores de enpp1 e seus usos para o tratamento de câncer
BR112015027951B1 (pt) Arilquinazolinas, seu uso e seu processo de produção, e composição farmacêutica
CN102317293A (zh) Raf抑制剂及其用途
CN112654622B (zh) 并环化合物、其制备方法及用途
EA032070B1 (ru) Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания
IL229988A (en) 4,4,4-trifluoro-n-[(1s)-2[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d] [3]benzazepine-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, its use in the manufacture of medicaments for treating cancer and crystalline hydrates thereof
US11529338B2 (en) Compositions and methods for treating cancer
JP7611934B2 (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
CA2927830A1 (en) Quinazolinone and isoquinolinone derivative
CN112055714B (zh) 二甲基氧膦类化合物
US20230056497A1 (en) CD206 Modulators Their Use and Methods for Preparation
WO2022089389A1 (zh) 杂环化合物及其制备方法、药物组合物和应用
WO2022242725A1 (zh) 一类新型蛋白降解剂及其应用
CN115724844A (zh) 一种具有抗肿瘤活性的杂环化合物及其用途
US20160250190A1 (en) N-methyl pyrazoloanthrone for treatment of cancer
EA021241B1 (ru) ОКСАЗОЛО[5,4-b]ПИРИДИН-5-ИЛЬНЫЕ СОЕДИНЕНИЯ
CN115215883A (zh) Usp7抑制剂
US20230026271A1 (en) Piperazine Compounds for Inhibiting CPS1
CN115304598B (zh) 一种杂环类化合物及其制备方法和用途
RU2812929C1 (ru) Ингибиторы mek и их терапевтическое применение